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Sustained Gene Expression in the Retina
by Improved Episomal Vectors
Sofia M. Calado, MSc,1–3 Ana V. Oliveira, MSc,1–3 Susana Machado, MSc,3
Rudolf Haase, PhD,4 and Gabriela A. Silva, PhD2,3
Gene and cellular therapies are nowadays part of therapeutic strategies for the treatment of diverse pathologies.
The drawbacks associated with gene therapy—low levels of transgene expression, vector loss during mitosis,
and gene silencing—need to be addressed. The pEPI-1 and pEPito family of vectors was developed to overcome
these limitations. It contains a scaffold/matrix attachment region, which anchors its replication to cell division
in eukaryotic cells while in an extrachromosomal state and is less prone to silencing, due to a lower number of
CpG motifs. Recent success showed that ocular gene therapy is an important tool for the treatment of several
diseases, pending the overcome of the aforementioned limitations. To achieve sustained gene delivery in the
retina, we evaluated several vectors based on pEPito and pEPI-1 for their ability to sustain transgene expression
in retinal cells. These vectors stably transfected and replicated in retinal pigment epithelial (RPE) cells.
Expression levels were promoter dependent with constitutive promoters cytomegalovirus immediate early
promoter (CMV) and human CMV enhancer/human elongation factor 1 alpha promoter yielding the highest
levels of transgene expression compared with the retina-specific RPE65 promoter. When injected in C57Bl6
mice, transgene expression was sustained for at least 32 days. Furthermore, the retina-specific RPE65 promoter
showed higher efficiency in vivo compared to in vitro. In this study, we demonstrate that by combining tissue-
specific promoters with a mitotic stable system, less susceptible to epigenetic silencing such as pEPito-based
plasmids, we can achieve prolonged gene expression and a sustained therapeutic effect.
Introduction
Over the last decades, gene therapy has been adriving force for the development of strategies to treat
genetic and acquired diseases. The major disadvantages of
DNA-based gene therapy are the epigenetic silencing due to
unmethylated CpG motifs present in the bacterial backbone
of plasmids grown in bacteria1 and vector loss during mi-
tosis, due to their incapacity to integrate the genome and
replicate in the host cell.2–4 The use of plasmids with the
capacity to replicate in mammalian cells, less frequent si-
lencing events, and species/tissue-specific promoters could
lead to sustained gene expression.4 To address these issues,
Piechaczek et al. developed a new vector, named pEPI-1,
which contains a scaffold/matrix attachment region
(S/MAR), derived from the human interferon b-gene.5 Other
authors have shown the involvement of the S/MARs in DNA
duplex destabilization and strand opening, suggesting these
sequences to be involved in DNA replication and gene
expression.6,7 Additionally, it was shown that the S/MAR-
containing vectors prevent epigenetic silencing of gene ex-
pression by shielding the transgene sequence from adjacent
regulatory sequences and heterochromatinization,8 main-
taining the vector in a transcriptionally active state.9 The
original pEPI-1 vector contains two mammalian transcrip-
tion units and a total of 305 CpG motifs, most of them
located in the elements of the vector required for bacterial
propagation. To reduce the CpG content in the bacterial
backbone of pEPI-1 and obtain increased transgene ex-
pression in vitro and in vivo, a new nonviral vector, pEPito,
was created by Haase et al.10 pEPito was constructed by
cloning the pEPI-1 plasmid replicon in a plasmid backbone
containing 60% less CpG motifs and excluding the second
transcription unit. A comparative study between pEPito and
pEPI-1 constructs showed pEPito-based vectors to be more
efficient, both in vitro and in vivo,10 explained by CpG
depletion of the bacterial backbone, which exhibits a strong
influence on epigenetic silencing events.1,10–12
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The eye is an attractive target for gene therapy because it is
an accessible and immune-privileged organ.13,14 Moreover,
due to its small size, only a small amount of a therapeutic agent
is necessary to observe a therapeutic effect.14 Diseases like
glaucoma, retinitis pigmentosa, and age-related macular de-
generation are blinding disorders that contribute to more than
25% of blindness cases, worldwide.15 The ineffectiveness of
current treatments makes these diseases ideal targets for gene
therapy.14,15 Moreover, in most cases, its genetic etiology is
well known and there is easy access to the photoreceptors or
retinal pigment epithelial/epithelium (RPE) by localized in-
jection.16 Studies with viral vectors, based on adeno-associated
viruses (AAVs), have as a major limitation, the small size of
the therapeutic gene that can be incorporated into the viral
vector.17 Therefore, our goal is to combine a nonviral vector
with an efficient gene expression system both in duration and
expression levels, to overcome the need of repeated injections,
thus increasing patient compliance.
In this study, pEPI-1- and pEPito-based vectors were
evaluated for their ability of sustained transgene expression
both in vitro, in RPE cells and in vivo, in the mouse retina.
We found pEPito to be an excellent gene expression system,
adequate for sustained gene expression.
Materials and Methods
pEPI-1- and pEPito-based vectors
Table 1 illustrates the five different plasmids tested in this
study, which are based on pEPI-1 and pEPito vectors.
The pEPI-1 vector contains an S/MAR sequence, derived
from the human interferon b-gene, two mammalian tran-
scription units, and a cytomegalovirus immediate early
promoter (CMV) constitutive promoter. The derivative pE-
Pito vectors contain an S/MAR sequence and four different
promoters: CMV promoter, human CMV enhancer/human
elongation factor 1 alpha promoter (hCMV), human CMV
enhancer/RPE65 (hCMV/RPE65), and RPE65, an RPE tis-
sue-specific promoter.18 pEPito vectors also contain an
eGFP-BSD cassette, in which an enhanced green fluorescent
protein (eGFP) and blasticidin (BSD) are expressed through
an internal ribosomal entry site. In addition to the promoter,
the backbones of the vectors vary in the CpG content and
size (between 5.2 and 7.8 kb).
Chemically competent Escherichia coli GT115 bacteria
(Invivogen) were transformed using 30 ng of each plasmid.
Transformed bacteria were selected on LB plates containing
either ampicillin (Sigma) or kanamycin (Sigma). After bacterial
propagation, pDNA was isolated using the QIAGEN Plasmid
Maxi Kit (Qiagen), according to the manufacturer’s instruc-
tions. The restriction map of the plasmids was confirmed using
endonuclease digestion and subsequent gel electrophoresis.
Transfection efficiency assay
In this study, the transfection efficiency of the plasmids
was evaluated in a human RPE cell line, D407. This cell line
was derived from an eyeball of a 12-year-old child.19 These
cells have been extensively used as a model of the retina and
retinal pigmented epithelium.20,21
D407 cells were cultured in Dulbecco’s modified Eagle’s
medium (Sigma) supplemented with 5% fetal bovine serum
(PAA), 1% of L-glutamine (Sigma), and 1% penicillin/
streptomycin (Sigma).
For the transfection assay, 2 · 105 cells were seeded in a
six-well tissue culture plate (Orange Scientific). Twenty-
four hours after plating, the cells were transfected with 1 mg
of DNA and FuGENE HD (Promega) as the transfection
reagent using a 3:1 (mL of FuGENE HD:mg of DNA) ratio,
according to the manufacturer’s instructions.
Forty-eight hours after transfection, cells were suspended,
washed three times with phosphate-buffered saline (PBS),
and GFP expression analyzed using a FACSCalibur (Becton
Dickinson) device and JDS Uniphase laser, with 100,000
events recorded.
Controls included nontransfected cells cultured in the
same conditions.
Colony-forming assay
Forty-eight hours post-transfection, D407 cells were
transferred from the six-well tissue culture plate to 10-cm
Petri dishes (BD Biosciences) and selected in the presence
of blasticidin (Sigma). Due to conflicting reports in the lit-
erature regarding the blasticidin concentration for selection
of stably transfected cells,22,23 we have determined the ad-
equate blasticidin concentration to select D407 transformed
cells by an MTT assay, where six different concentrations of
blasticidin were tested—0.01, 0.1, 1, 3, 5, and 10mg/mL. The
selected concentration of blasticidin was 1mg/mL (Supple-
mentary Fig. S1; Supplementary Data are available online at
www.liebertpub.com/tea).
After 32 days of selection with blasticidin, three colonies
of each plasmid were extracted and maintained in culture for
2 additional months under selection (up to 3 months in to-
tal), with eGFP-positive cells quantified by flow cytometry
as described in the previous section.
The remaining colonies were fixed with 4% paraformal-
dehyde (PFA; Sigma) in PBS, stained with 2% methylene
blue in methanol (VWR), and counted.
Table 1. pEPI and pEPito Vectors Used in This Study
Plasmid Size (kb) Backbone Promoter Transgene CpG motifs (backbone)
pEPI-1 6.7 pEPI CMV eGFP 206
pEPito-CMV-eGFP 5.3 pEPito CMV BSD-eGFP 37
pEPito-hCMV-eGFP 5.2 pEPito hCMV BSD-eGFP 37
pEPito-RPE65-eGFP 7.5 pEPito RPE65 BSD-eGFP 37
pEPito-hCMV/RPE65-eGFP 7.8 pEPito hCMV/RPE65 BSD-eGFP 37
BSD, blasticidin; CMV, cytomegalovirus immediate early promoter; hCMV, human CMV enhancer/human elongation factor 1 alpha
promoter; eGFP, enhanced green fluorescent protein; RPE, retinal pigment epithelial.
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Injection of pEPito vectors in C57Bl6 mice
and eGFP expression
To test the in vivo efficiency of the pEPito-derived vec-
tors, FuGENE HD-plasmid complexes were injected into the
eye of C57Bl6 mice pups. All methods involving animals
were performed according to the ARVO Statement for the
Use of Animals in Ophthalmic and Vision Research. Litters
and nursing dams were housed in plastic cages in a patho-
gen-free environment, with continuous access to food and
water on a 12-h light–12-h dark schedule.
The DNA-FuGENE complex used in vivo was prepared by
mixing 2mg of plasmid DNA and 1mL of FuGENE HD in a
total volume of 20mL of PBS. Pups at postnatal age of 5 days
(P5) were anesthetized on ice. Using a needle, the sclera was
punched in the temporal side and 1mL of the DNA-FuGENE
complex was injected into the vitreous cavity. After the injec-
tion, a topical ointment consisting of gentamicin and prednis-
olone acetate was applied to reduce the pain and the risk of
infection. The contralateral noninjected eye was used as control.
At 3, 7, 14, 21, and 32 days postinjection (dpi), eight mice
per plasmid DNA were humanely sacrificed, the eyes enu-
cleated, and fixed in ice-cold 4% PFA in PBS, for 24 h. This
was followed by an overnight immersion in 30% sucrose
(Sigma) in a PBS solution and embedded in OCT (Tissue-
Tek) for cryosection. Ten-micrometer-thick serial sections
were performed, counterstained with DAPI and mounted
with Fluoromount G (Electron Microscopy Sciences).
In vivo transfection was evaluated by eGFP expression
using an AxioImager Z2 Fluorescence microscope (Zeiss),
with AxioCam HRm and magnifications of 50 · and 200· .
The transfected area was quantified using ImageJ software,
by quantifying both the GFP-positive and the ganglion cell
layer (GCL) areas, and calculating the percentage of GFP-
positive area relative to the GCL area.
Statistical analyses
Statistical analyses were performed using the SPSS Soft-
ware, version 19.0.
One-way ANOVA was used to compare the in vitro
transfection efficiency of the different plasmids and the
in vitro colony-forming efficiency of stably selected D407
cells. In the event of a significant ANOVA, the Tukey test
was used for post hoc analysis.
Data are expressed as mean – standard deviation and
*p < 0.05.
Results
Transfection efficiency of pEPI-1 and pEPito
in RPE cells is promoter dependent
In vitro experiments were performed in D407 human RPE
cells, and transfection efficiency was analyzed by flow cy-
tometry for eGFP-positive cells, 48 h post-transfection.
Our results showed that plasmids pEPito-CMV, pEPito-
hCMV, and pEPI-1, containing either the CMV or hCMV
constitutive promoters, presented transfection efficiencies in
the range of 30% (Fig. 1). The plasmid containing the hCMV
enhancer element and the RPE65 promoter (pEPito-hCMV/
RPE65) had the lowest transfection efficiency (6%), com-
pared with the plasmids containing either the CMV or hCMV
promoters (Fig. 1). No eGFP-positive cells were detected in
conditions transfected with pEPito-RPE65 (Fig. 1), and for
this reason, this vector was not further tested in vitro.
pEPito plasmids express eGFP for 3 months
in mitotically active RPE cells
As previously stated, one of the major advantages of the
S/MAR-containing plasmids is their ability to be maintained
in an episomal state and to be replicated during mitosis.9
This eliminates one of the major drawbacks of plasmid gene
therapy—the vector dilution effect—occurring during cell
division. To test the capacity of these plasmids to replicate
during cell division and to form a stable transfected cell col-
ony, D407 cells were transfected with pEPito-CMV, pEPito-
hCMV, and pEPito-hCMV/RPE containing the blasticidin
resistance gene (BSD), for mammalian cell selection. Our
assay to determine the lowest blasticidin concentration to se-
lect pEPito-modified cells showed this value to be 1mg/mL
(Supplementary Fig. S1). This concentration was used in all
the selection experiments.
All tested plasmids were able to originate stably trans-
fected colonies of D407 cells (Fig. 2).
We found that the plasmids containing either hCMV or
CMV promoter were more efficient establishing stable colo-
nies than the plasmid containing the cell-specific promoter
(Fig. 3). The plasmid that originated a higher number of col-
onies after 32 days of selection was pEPito-hCMV, with an
average of 510 colonies (Fig. 3). pEPito-CMV originated 360
colonies (Fig. 3) and for pEPito-hCMV/RPE65, the number of
colonies formed was markedly lower, resulting in about 200
colonies (Fig. 3). This result was not surprising because pE-
Pito-hCMV/RPE65 had a lower transfection efficiency (Fig. 1)
compared with the plasmids containing either CMV or hCMV
promoter. This result indicates a direct correlation between the
transfection efficiency and the number of formed colonies.
FIG. 1. Transfection efficiencies for transiently trans-
fected D407 cells with the five different plasmids. Mean
values are derived from four independent experiments
and statistical significance was determined with one-way
ANOVA followed by a post hoc Tukey Test. The statisti-
cal difference is indicated by a star (*) symbol (*p < 0.05).
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After 1 month of selection, the intensity of the fluores-
cence decreased over time in the colonies transfected with
pEPito-CMV. On the other hand, in the colonies transfected
with pEPito-hCMV, the intensity of fluorescence remained
high. These results were further confirmed by flow cytom-
etry: after 2 months of selection, eGFP expression was de-
tected and about 19% of the cells transfected with pEPito-
hCMV presented fluorescence (Fig. 4B). However, only 3%
of the cells transfected with pEPito-CMV presented fluo-
rescence (Fig. 4C) and 1% of cells with pEPito-hCMV/
RPE65 (Fig. 4D). After 3 months of selection, almost no
eGFP-positive cells were detected in cells transfected with
either pEPito-CMV or pEPito-hCMV/RPE65 (Fig. 4G, H).
In contrast, 2% of the cells transfected with pEPito-hCMV
remained fluorescent (Fig. 4F).
pEPI and pEPito gene transfer to mouse retinas
An intravitreal injection of 1 mL solution of each plasmid
DNA and FuGENE (containing 100 ng of plasmid DNA)
was performed in 5-day postnatal (P5) C57Bl6 mice. After
the injection procedure, the eyes had a normal appearance
and an absence of inflammation similar to the noninjected,
contralateral eye.
At 3, 7, 14, 21, and 32 dpi, the eGFP expression was
analyzed in 10mm eye sections. Since the administration
method was by intravitreal injection, we expected the retinal
GCL to be transfected, because it was in direct contact with
the vitreous cavity and with the injection site. Indeed, we
have observed that the cells expressing the GFP were
clustered along the border of the GCL (Fig. 5).
The overall analysis of the retinal sections showed that the
eGFP was expressed by all plasmids, up to 32 days after in-
jection. Table 2 shows the number of retinas, per plasmid and
per time point, where eGFP expression was detected. Since it
was not possible to follow the same animal over time, the results
are shown as number of retinas (animals) with eGFP expression.
As expected, 3 dpi was the time point in which less retinas
exhibited GFP expression, as this is too short a time period
for the cellular machinery to start the transcription of the
genetic material within the plasmid. The number of retinas
FIG. 2. Brightfield (A) and fluorescence (B) microscopy of a stably transfected D407 cell line colony with pEPito-CMV-eGFP-
BSD (1), pEPito-hCMV-eGFP-BSD (2), and pEPito-hCMV/RPE65-eGFP-BDS (3)32days post-transfection.BSD,blasticidin;CMV,
cytomegalovirus immediate early promoter; hCMV, human CMV enhancer/human elongation factor 1 alpha promoter; eGFP,
enhanced green fluorescent protein; RPE, retinal pigment epithelial. Color images available online at www.liebertpub.com/tea
FIG. 3. Colony-forming efficiency of D407 cells selected
with blasticidin, for each of the pEPito plasmids. Mean
values are derived from three independent experiments and
statistical significance was determined with one-way AN-
OVA followed by a post hoc Tukey Test. Bars labeled with
* indicate statistical difference ( p< 0.05).
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eGFP-positive was lower for both pEPI-1 and pEPito-CMV
than for pEPito-hCMV.
Even though the in vitro experiments using pEPito-
hCMV/RPE65 had lower transfection efficiencies than those
containing either the CMV or hCMV promoter, this result
was reverted in vivo, since the number of retinas expressing
the eGFP was comparable to the one observed for pEPito-
hCMV. As expected, no fluorescence was detected in the
retinas of the contralateral noninjected eye (Fig. 5A, B).
After quantification, we conclude that the transfected area
was about 1.5–2% of the GCL area. This area was not af-
fected by the plasmid used.
Discussion
In this study, the potential of plasmids containing S/
MARs, pEPI-1, and its derivative pEPito, as expression
systems for gene transfer to the retina, was tested in vitro
and in vivo. The aim was to assess whether these expression
systems could sustain prolonged expression in the retina, as
observed previously for the liver.8–10,24
Our transfection assay showed that in D407 retinal
cells, the constructs with the RPE-specific promoter were
less efficient than the constructs with either the CMV or
hCMV promoter. One possible explanation lies in the fact
that plasmids containing the RPE65 promoter are larger
(7.8 kb, Table 1) than the ones with the constitutive pro-
moter (5.2–6.7 kb, Table 1), and since the in vitro exper-
iments were performed by transfecting the same amount
(in mass) of plasmid DNA and not equimolar ratios of
vector molecules that may account for differences re-
garding the higher transfection efficiencies observed for
the smaller plasmids.
Our colony-forming assay, aimed at testing the ability of
these vectors to be replicated during mitosis, showed that all
plasmids were able to originate stably transfected colonies for
at least 32 days post-transfection. pEPito-hCMV originated
the highest number of colonies and pEPito-hCMV/RPE65 the
lowest. The latter result was expected since pEPito-hCMV/
RPE65 had a lower transfection efficiency compared with the
plasmids with either CMV or hCMV promoter. Moreover,
cells from the colonies transfected with pEPito-hCMV
maintained GFP expression for 2 further months, whereas in
colonies transfected with pEPito-CMV or pEPito-hCMV/
RPE65, no GFP-positive cells were detected after this period.
This result emphasizes the importance of the promoter in the
expression profile of a gene, with the CMV promoter being
more susceptible to silencing by epigenetic events than the
hCMV promoter. Moreover, the plasmids were able to stably
replicate for over 100 cell divisions in vitro, indicating that
in vivo, in mostly postmitotic retinal cells, gene expression
will be maintained for a prolonged time.
In vivo, our results evidence that all plasmids were able to
express the eGFP in mouse retinas for at least 32 dpi. The
number of retinas expressing eGFP was lower for pEPI-1 and
for pEPito-CMV than for pEPito-hCMV, which indicates that in
the plasmids containing the CMV promoter, the eGFP expres-
sion was silenced. This result is supported by the literature,
where it is described that plasmids with a higher CpG content
either in the backbone or in the promoter are more susceptible
to epigenetic silencing events,1,11,12 and the pEPI-1 and pEPito-
CMV have more CpG motifs than the pEPito-hCMV.10 This
result supports the importance of a CpG-depleted vector/
promoter for a sustained gene expression profile.
On the other hand, we observed a higher number of ret-
inas displaying fluorescence in the eyes injected with
FIG. 4. Flow cytometry of D407 colonies stably transfected with pEPito-hCMV (B, F), pEPito-CMV (C, G), and pEPito-
hCMV/RPE65 (D, H). Upper panels represent cells after 2 months of selection with BSD, and lower panels correspond to
cells after 3 months of selection. (A) and (E) are the control nontransfected cells.
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pEPito-hCMV than with pEPito-CMV. This is in accor-
dance to what is described by Haase et al.,10 which has
shown these plasmids to originate the strongest luciferase
expression in vivo, as the hCMV promoter is less affected by
epigenetic silencing events than CMV.12
Although our in vivo study has shown a low number of
transfected cells, upon comparison with other studies, where
these systems were combined with chitosan nanoparticles
for corneal gene delivery25 or AAVs used for retinal
transduction,26 the amount of DNA we used was signifi-
cantly lower than in other studies (100 ng compared with
1.5 mg25). However, our results show that by using only
100 ng of DNA, we could achieve a transfection efficiency
of 1.5–2% of the ganglion cells.
Finally, pEPito-hCMV/RPE65 showed a lower transfec-
tion efficiency than other plasmids in our in vitro experi-
ments, but a greater efficiency in vivo, which highlights
the relevance of a tissue-specific promoter. Moreover, the
expression of the pEPito-hCMV/RPE65 containing an RPE-
specific promoter observed in ganglion cells can be ex-
plained by the presence of the hCMV enhancer, which has
been described as a strongly potentiating gene expression.
With this study, we prove that these improved episomal
vectors containing S/MARs and less CpGs—the pEPitos—
can be used for efficient gene transfer to the retina. The
combination of an enhancer that is less affected by epige-
netic silencing effects with a tissue-specific promoter is
FIG. 5. Transversal sections of a
mouse retina injected with pEPI-1-
and pEPito-based vectors, sacri-
ficed 32 days postinjection. * In-
dicates clusters of eGFP-expressing
ganglion cells transfected with pE-
Pito-hCMV (A) (magnification:
50 · ); (B) corresponds to an am-
plification of image (A) (magnifi-
cation: 200· ), pEPito-CMV (C)
(magnification: 200 · ), pEPI-1 (D),
and pEPito-hCMV/RPE65 (E). (F)
A noninjected retina, without GFP
expression. DAPI (blue) stains nu-
clei. GCL, ganglion cell layer; INL,
inner nuclear layer; OPL, outer
plexiform layer. Color images
available online at www.liebertpub
.com/tea
Table 2. Summary of the Number
of GFP-Positive Retinas (n = 8)
dpi pEPi-1 pEPito-CMV pEPito-hCMV
pEPito-hCMV/
RPE65
3 1 0 4 3
7 3 3 6 4
14 4 4 5 5
21 4 4 5 5
32 3 3 5 4
dpi, days postinjection.
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crucial to sustain a prolonged gene expression in vivo and
contribute for an efficient gene therapy strategy.
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